1.  Randomized studies of sealants in lung surgery.

Authors	Sealant	Nº patients	Air leaks duration	Days chest tube	Prolonged air leaks	Days hospitalization	Empyema
Fleisher	Fibrin glue	Treatment: 14	3.2	6.1	14%*	9.8	0%
		Control: 14	3.3	5.9	7%	11.5	0%
		Signif.	NS	NS	NS	NS
Wong	Fibrin glue	Treatment: 33	5	6		8	0%
		Control: 33	4	6		9	3%
		Signif.	NS	NS		NS
Mouritzen	Fibrin glue	Treatment: 55	4	3		9
		Control: 59	5	4		10
		Signif.	NS	NS		NS
Macchiarini	Advaseal	Treatment: 13	1.9	6.1		13	3,8%
		Control: 11	2.4	6.4		14	0%
		Signif.	NS	NS		NS
Porte	Advaseal	Treatment: 59	33.7 h		13%	9.2	6.78%
		Control: 61	63.22 h		22%	8.59	0%
		Signif.	S		NS	NS	NS
Wain	Focal Seal	Treatment: 117	30.9 h	4.5	2.5%	7.4	3%
		Control: 55	52.3 h	5.2	7%	10.1	0%
		Signif.	S	NS	NS	NS	NS
Allen	Bioglue	Treatment: 95	2	6.8		6	0%
		Control: 53	2	6.2		7	0%
		Signif.	NS	NS		S
Fabian	Fibrin glue	Treatment: 50	1.1	3.5	2%	4.6	0%
		Control: 50	3.1	5	16%	4.9	0%
		Signif.	S	S	S	NS
Lang	TachoComb	Treatment: 96	1.7
		Control: 93	2
		Signif.	NS
Belboul	Vivostat	Treatment 20		1		4
		Control 20		3		4.5
		Signif.		NS		NS
Wurtz	Fibrin glue	Treatment 25				11,4	0%
		Control 25				13	0%
		Signif.				NS
Wurtz	Fibrin glue	Treatment 25				9,9	0%
		Control 25				10,6	0%
		Signif.				NS
Marta	TachoSil	Treatment 149	‐	4.9
		Control 150	‐	5.5
		Signif.	S	NS
Droghetti	TachoSil	Treatment 20	1.7	7.6	5%	14.3	0%
		Control 20	3.7	10.2	20%	11.0	0%
		Signif.	S	NS	NS	NS
Anegg	TachoSil	Treatment 75		5.1	24%	6.2	0%
		Control 77		6.3	32.46%	7.7	0%
		Signif.		S	S	S
Tansley	Bio glue	Treatment 27	1	4	11%	6	0%
		Control 25	4	5	8%	7	0%
		Signif.	S	S		S